Nyxoah S.A. (NYXH)
USD 6.12
(1.75%)
USD 6.12
(1.75%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 3.31 Million EUR | 275.85% |
| 2022 | 882 Thousand EUR | 154.91% |
| 2021 | 346 Thousand EUR | 529.09% |
| 2020 | 55 Thousand EUR | 0.0% |
| 2019 | - EUR | 100.0% |
| 2018 | -732 Thousand EUR | -27.3% |
| 2017 | -575 Thousand EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 3.41 Million EUR | 3.11% |
| 2024 Q2 | 5.09 Million EUR | 49.15% |
| 2023 Q1 | 1.24 Million EUR | 41.61% |
| 2023 Q3 | 1.7 Million EUR | 49.13% |
| 2023 Q4 | 3.31 Million EUR | 93.97% |
| 2023 Q2 | 1.14 Million EUR | -8.25% |
| 2023 FY | 3.31 Million EUR | 275.85% |
| 2022 Q1 | 301 Thousand EUR | -13.01% |
| 2022 FY | 882 Thousand EUR | 154.91% |
| 2022 Q4 | 882 Thousand EUR | 48.48% |
| 2022 Q3 | 594 Thousand EUR | 17.39% |
| 2022 Q2 | 506 Thousand EUR | 68.11% |
| 2021 Q4 | 346 Thousand EUR | 0.0% |
| 2021 FY | 346 Thousand EUR | 529.09% |
| 2021 Q2 | 83 Thousand EUR | -21.7% |
| 2021 Q1 | 106 Thousand EUR | 92.73% |
| 2020 Q1 | - EUR | 100.0% |
| 2020 Q4 | 55 Thousand EUR | 0.0% |
| 2020 Q3 | 55 Thousand EUR | -93.01% |
| 2020 Q2 | 787 Thousand EUR | 0.0% |
| 2020 FY | 55 Thousand EUR | 0.0% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 Q4 | -2.1 Million EUR | 0.0% |
| 2019 Q3 | - EUR | 0.0% |
| 2019 FY | - EUR | 100.0% |
| 2018 FY | -732 Thousand EUR | -27.3% |
| 2017 FY | -575 Thousand EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 17.87 Million USD | 81.457% |
| AngioDynamics, Inc. | 60.61 Million USD | 94.531% |
| AtriCure, Inc. | 67.89 Million USD | 95.118% |
| Avinger, Inc. | 5.29 Million USD | 37.429% |
| Azenta, Inc. | 128.19 Million USD | 97.414% |
| BioLife Solutions, Inc. | 43.45 Million USD | 92.372% |
| The Cooper Companies, Inc. | 735.6 Million USD | 99.549% |
| Daxor Corporation | - USD | -Infinity% |
| Ekso Bionics Holdings, Inc. | 5.05 Million USD | 34.356% |
| Femasys Inc. | 667.11 Thousand USD | -396.914% |
| GlucoTrack, Inc. | - USD | -Infinity% |
| Harvard Bioscience, Inc. | 24.71 Million USD | 86.588% |
| Hologic, Inc. | 679.8 Million USD | 99.512% |
| ICU Medical, Inc. | 709.36 Million USD | 99.533% |
| Intuitive Surgical, Inc. | 1.22 Billion USD | 99.728% |
| KORU Medical Systems, Inc. | 3.48 Million USD | 4.777% |
| LeMaitre Vascular, Inc. | 52.33 Million USD | 93.666% |
| Innovative Eyewear, Inc. | 856.75 Thousand USD | -286.923% |
| Innovative Eyewear, Inc. | 856.75 Thousand USD | -286.923% |
| Masimo Corporation | 545 Million USD | 99.392% |
| Microbot Medical Inc. | - USD | -Infinity% |
| Meihua International Medical Technologies Co., Ltd. | 1.61 Million USD | -104.981% |
| Merit Medical Systems, Inc. | 303.87 Million USD | 98.909% |
| Nephros, Inc. | 2.47 Million USD | -34.211% |
| NovoCure Limited | 38.15 Million USD | 91.311% |
| NEXGEL, Inc. | 1.31 Million USD | -151.327% |
| NEXGEL, Inc. | 1.31 Million USD | -151.327% |
| Singular Genomics Systems, Inc. | 13.57 Million USD | 75.575% |
| OraSure Technologies, Inc. | 47.61 Million USD | 93.038% |
| Pro-Dex, Inc. | 15.26 Million USD | 78.289% |
| Pulse Biosciences, Inc. | - USD | -Infinity% |
| Predictive Oncology Inc. | 494.37 Thousand USD | -570.545% |
| Precision Optics Corporation, Inc. | 2.86 Million USD | -15.582% |
| QuidelOrtho Corporation | 577.8 Million USD | 99.426% |
| Repligen Corporation | 202.32 Million USD | 98.362% |
| Sanara MedTech Inc. | 4.71 Million USD | 29.73% |
| STAAR Surgical Company | 35.13 Million USD | 90.564% |
| Sharps Technology, Inc. | 1.7 Million USD | -93.958% |
| Utah Medical Products, Inc. | 9.58 Million USD | 65.404% |
| DENTSPLY SIRONA Inc. | 624 Million USD | 99.469% |
| Jin Medical International Ltd. | 5.05 Million USD | 34.397% |